FDA approves first cell therapy for multiple myeloma
The Food and Drug Administration late Friday night gave the green light to a fifth CAR-T medicine — but this one is the first personalized cell therapy approved to treat multiple myeloma. It's also the first approved to target the BCMA protein.
Abecma, made by Bristol Myers Squibb and Bluebird Bio, will cost $419,500, and is only meant to be used in patients who have failed four or more previous lines of therapy.
“This is a new chapter and a new opportunity for patients and caregivers in myeloma,” one multiple myeloma expert told STAT’s Adam Feuerstein. “We now have a new modality, if you want to call it that, for myeloma therapy, so it’s very exciting and likely the first of many such approvals.”